Drug data last refreshed 16h ago · AI intelligence enriched 4w ago
ORTHO TRI-CYCLEN 21 is an oral contraceptive combining ethinyl estradiol and norgestimate in a triphasic formulation designed to provide cycle control and contraceptive efficacy. The product uses a 21-day active tablet regimen followed by 7 days of hormone-free interval. It is indicated for prevention of pregnancy in women who elect to use this product as a method of contraception.
Product is in late-stage lifecycle phase with moderate competitive pressure (30), indicating defensive positioning and smaller commercial teams focused on retention rather than growth.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on ORTHO TRI-CYCLEN 21 provides experience in defending a mature brand against generic and therapeutic competition within the high-volume women's health market. Roles are primarily commercial and defensive, emphasizing retention marketing, pricing strategy, and market access rather than innovation and growth.
Worked on ORTHO TRI-CYCLEN 21 at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.